New vaccine combo takes on Hard-to-Treat cancers
NCT ID NCT06411691
First seen Nov 20, 2025 · Last updated May 19, 2026 · Updated 23 times
Summary
This early-phase study tests a combination of a vaccine targeting mutant KRAS proteins and two immunotherapy drugs (balstilimab and botensilimab) in adults with advanced colorectal or pancreatic cancer that has not responded to first-line chemotherapy. The goal is to see if the treatment can shrink tumors or slow disease progression. About 54 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.